← Back to Clinical Trials
Recruiting NCT06910891

NCT06910891 Hemodynamic Evaluation Using Microcirculation for Early Treatment of Septic Patients

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT06910891
Status Recruiting
Phase
Sponsor University Hospital, Limoges
Condition Sepsis
Study Type INTERVENTIONAL
Enrollment 556 participants
Start Date 2025-09-20
Primary Completion 2027-03-28

Eligibility & Interventions

Sex All sexes
Min Age 18 Years
Max Age N/A
Study Type INTERVENTIONAL
Interventions
measurement of the peripheral perfusion index and marbling assessment

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 556 participants in total. It began in 2025-09-20 with a primary completion date of 2027-03-28.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

Despite early treatment, the deterioration and mortality of sepsis patients remains high. A possible explanation could be persistent tissue hypoperfusion, or undetected in the early phase despite the normalization of macro-hemodynamic parameters. This interventional study evaluates the impact of measuring microcirculation parameters by nurses on patient prognosis through early initiation of vascular filling.

Eligibility Criteria

Inclusion Criteria: 1. Age ≥ 18 years 2. Admitted to the Emergency Department for suspected Sepsis for less than 6 hours according to international Sepsis-3 definitions (high probability of infection defined by a fever greater than or equal tol to 38.3°C with a suspected infectious source + Score NEWS 2 greater than or equal to 2) 3. Affiliated to a social security system 4. Having agreed to participate in this study Exclusion Criteria: 1. Patient with arterial hypotension (SBP ≤ 100 mmHg) on admission 2. Patient having already received a 500mL filling test over 30 minutes 3. Patients moribund according to the investigator 4. Pregnancy or breastfeeding 5. Patient under guardianship, curatorship or safeguard of justice

Contact & Investigator

Central Contact

Anaelle NARDOT-SUCHAUD

✉ Anaelle.NARDOT-SUCHAUD@chu-limoges.fr

📞 0519761835

Frequently Asked Questions

Who can join the NCT06910891 clinical trial?

This trial is open to participants of all sexes, aged 18 Years or older, studying Sepsis. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT06910891 currently recruiting?

Yes, NCT06910891 is actively recruiting participants. Contact the research team at Anaelle.NARDOT-SUCHAUD@chu-limoges.fr for enrollment information.

Where is the NCT06910891 trial being conducted?

This trial is being conducted at Brivé, France, Guéret, France, Limoges, France, Saint-Junien, France and 2 additional locations.

Who is sponsoring the NCT06910891 clinical trial?

NCT06910891 is sponsored by University Hospital, Limoges. The trial plans to enroll 556 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology